Akèy › Timè nan sèvo › Massachusetts › Boston
Etid klinik pou Timè nan sèvo nan Boston, MA
28 etid pou Timè nan sèvo ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Ap rekriteFaz 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Ap rekriteFaz 1/2
- Tufts Medical Center, Boston
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Ap rekriteFaz 1/2
- Dana-Farber Cancer Institute, Boston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Ap rekriteFaz 2
- Local Institution - 0124, Boston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
Ap rekrite
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Ap rekriteFaz 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Ap rekriteFaz 1/2
- Dana-Farber Cancer Institute, Boston
Targeted Pediatric High-Grade Glioma Therapy
Ap rekriteEtid obsèvasyon
- Dana-Farber Cancer Institute, Boston
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Ap rekriteFaz 2
- Massachusetts General Hospital, Boston
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
Ap rekriteFaz 2
- Brigham and Women's Hospital / Dana-Farber Cancer Institute, Boston
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
Ap rekriteFaz 2
- Brigham and Women's Hospital, Boston
B7-H3.CD28Z.CART in CNS Neoplasms
Ap rekriteFaz 1
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study of Olutasidenib and Temozolomide in HGG
Ap rekriteFaz 2
- Susan Chi, Boston
Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy
Ap rekrite
- Massachusetts General Hospital, Boston
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Ap rekriteEtid obsèvasyon
- Beth Israel Deaconess Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
Palbociclib and Pembrolizumab In Central Nervous System Metastases
Ap rekriteFaz 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
Ap rekriteFaz 3
- Tufts Medical Center, Boston
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Ap rekriteFaz 2
- Dana-Farber Cancer Institute, Boston
NTS-WBRT in Brain Metastases
Ap rekriteFaz 2
- Massachusetts General Hospital Cancer Center, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
NeuroPathways Intervention for Brain Tumor Patients
Ap rekrite
- Massachusetts General Hospital Cancer Center, Boston
Stereotactic Magnetic Resonance Guided Radiation Therapy
Ap rekrite
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
Ap rekriteFaz 1 bonè
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Ap rekriteFaz 1/2
- Beth Israel Deaconess Medical Center, Boston
ASCENT Intervention for Brain Tumor Patients
Ap rekrite
- Massachusetts General Hospital Cancer Center, Boston
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Ap rekriteEtid obsèvasyon
- Massachusetts General Hospital, Boston
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Ap rekriteEtid obsèvasyon
- Massachusetts General Hospital, Boston
Etid Timè nan sèvo nan lòt vil
- Houston, TX35 etid
- New York City, NY25 etid
- Washington, DC20 etid
- Los Angeles, CA16 etid
- Miami, FL15 etid
- Durham, NC14 etid
- St. Louis, MO12 etid
- Cleveland, OH11 etid
- Seattle, WA11 etid
- Rochester, MN11 etid
- Baltimore, MD11 etid
- Columbus, OH11 etid
Lòt etid nan Boston
- Kansè nan tete111 etid
- Kansè Poumon ki pa ti selil90 etid
- Kansè (tout kalite)86 etid
- Kansè kolorektal63 etid
- Kansè Metastatik63 etid
- Kansè poumon62 etid
- Kansè ovè61 etid
- Kansè pwostat59 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Ensifizyans kadyak44 etid
- Leksemi mieloïd egi44 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.